Loxat 30,0 mg/10,0 mg/300,0 mg Concentrate solution for infusion
PDF Leaflet Revision Date: 26 November 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Palliative treatment of advanced ovarian, breast, and non-small cell lung cancer.
Dosage (summary)
Ovarian carcinoma: 135 mg/mu00b2 over 24 hours + cisplatin 75 mg/mu00b2 every 3 weeks. Metastatic carcinoma: 175 mg/mu00b2 IV over 3 hours every 3 weeks.
Special Populations
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy; not known if excreted in breast milk.
Key Drug Interactions
- Cisplatin
- Ketoconazole
- Doxorubicin
Contraindications
- Severe hypersensitivity to paclitaxel
- Baseline neutrophils < 1500/mmu00b3
Common side effects
- Neutropenia
- Peripheral neuropathy
- Hypersensitivity reactions
Counselling Points
- Premedicate with corticosteroids and antihistamines
- Monitor blood counts regularly
- Avoid pregnancy during treatment
Serious warnings
- Severe hypersensitivity reactions
- Bone marrow suppression
- Cardiovascular events
Important Disclaimer
The Loxat 30,0 mg/10,0 mg/300,0 mg Concentrate solution for infusion professional information leaflet below is the property of Oethmaan Biosims and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
